Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.

Key Inclusion Criteria:

• Subjects ≥18 and <75 years of age
• Presence of moderate to severe dry eye disease (DED) in at least one eye

Key Exclusion Criteria:

• Presently using prescription eyedrops, except those used for dry eye disease, which must be discontinued 4 weeks prior
• Use of over-the-counter (OTC) eyedrops except for lubricant eyedrops or artificial tears, within 1 week prior to initiation of study drug dosing
• History or evidence of ocular infection within the previous 30 days
• Blepharitis or meibomian gland disease requiring the use of either topical or systemic antibiotics within 2 months
• Allergic conjunctivitis requiring treatment within 30 days
• Unable to discontinue contact lens wear for 2 weeks prior and for the duration of the study